Mirus Bio Corp., of Madison, Wis., received U.S. Patent No. 7,148,205, titled "Intravascular Delivery of Non-Viral Nucleic Acid." It covers administration of RNAi-inducing molecules via hydrodynamic intravascular injection.
NanoMed Pharmaceuticals Inc., of Kalamazoo, Mich., received U.S. Patent No. 7,153,525, titled "Microemulsions As Precursors To Solid Nanoparticles. It covers processes and application of Nanotemplate Engineering, which is used for formulate small molecules, peptides, proteins, plasmid DNA and diagnostic agents.
Prometheus Laboratories Inc., of San Diego, was issued U.S. Patent No. 7,138,237, which covers the diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen.
ScinoPharm Taiwan Ltd., of Tainan, Taiwan, received U.S. Patent No. 7,151,179, titled "Process for the Preparation of 7-Alkyl-10-Hydroxy-20 - Camptothecin," which relates to the preparation of SN-38, an intermediate in the synthesis of irinotecan.
Stem Cell Innovations Inc., of Houston, received U.S. Patent No. 7,153,684, covering human pluripotent stem cells, specifically isolated human primordial germ cell-derived pluripotent stem cells.